As quoted in the press release:
Dear Shareholders of M Pharmaceutical Inc.,
Welcome to the summer of 2017 and the one-year anniversary of launching a new and exciting direction for M Pharmaceutical Inc. I am pleased to announce that in these past 12 months, M Pharma has executed on several significant growth initiatives as they relate to the Company’s market prospects and enhancement of value to our shareholders. As previously announced, the Company has added to its portfolio C-103, the re-formulated Orlistat project, the global marketing rights to ToConceive, and acquired the assets of Cincinnati based 40J’s LLC. These new assets include current distribution revenues of roughly $170K+ quarterly, eight patented and patent pending pipeline technologies, one of which is the new drug Extrinsa for female sexual dysfunction.